Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma: A commentary

Cancer

Volumn 91, Issue 5, 2001, Pages 881-888

  Nathanson, Larry ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Adjuvant trials; Immunotherapy; Melanoma; Multiple primary malignancy; Pathogenesis; Prevention

Indexed keywords

ALPHA TOCOPHEROL; BCG VACCINE; RETINOID; SELENIUM; TAMOXIFEN;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; HUMAN; MELANOMA; NEVUS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; REVIEW; RISK MANAGEMENT; XERODERMA PIGMENTOSUM;

CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; MELANOMA; RESEARCH DESIGN; RISK FACTORS;

EID: 0035282124     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010301)91:5<881::AID-CNCR1077>3.0.CO;2-W     Document Type: Review

References (41)

1. The annual report to the bation on the status of cancer, 1973-1997, with a special section on colorectal cancer
2. The pathogenesis of melanoma induced by ultraxiolet radiation
3. Parallel risk assessment of melanoma and basal cell carcinoma: Skin characteristics and sun exposure
4. Clinical and histopathological characteristics in relation to etiological risk factors in cutaneous melanoma: A population-based study
5. p53 expression and risk factors for cutaneous melanoma: A case control study
6. Naevus-associated melanomas: Cause or chance?
7. Human ned are clonal
8. A genetic model for colon carcinogenesis
9. The authors reply
10. Cancer chemoprevention: Progress and promise
11. Primary prevention activities for malignant melanoma in the United States
12. Effects of topical tretinoin on dysplastic nevi
13. Effect of topical tretinoin under occlusion on atypical naevi
14. BCG vaccination and the subsequent risk of cancer in humans
15. Adjuvant therapy for cutaneous melanoma
16. Melanoma vaccines
17. Correlation of specific immune response with survival in melanoma patients with distant metastases receiving polyvalent melanoma vaccine
18. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma
19. Cancer testis antigens: Targets for cancer immunotherapy
20. Diabetes mellitus induced by low dose interleukin-2
21. Successful adjuvant therapy of melanoma mandates second primary risk reduction endpoints in future trials
22. Randomized trial of vitamin A versus observation as adjuvant therapy in high risk primary malignant melanoma: A Southwest Oncology Group study
23. Public education and cancer of the skin
24. Xermaderma pigmentosa: Cutaneous ocular and neuralgic abnormalities in 830 published cases
25. Werner's syndrome: What does an aging syndrome gene reveal about cancer?
26. BRCA 1-mutations in two pedigrees with breast cancer and melanoma
27. Multiple primary melanomas: Incidence and risk factors in 283 patients
28. Multiple primary melanomas: An analysis of cancer registry data from Victoria and NSW
29. Multiple primary, melanomas: Implications for screening and follow-up programs for melanomas
30. Multiple primary melanomas: Analysis of 49 cases
31. Risk of melanoma and other cancers melanoma-prone families
32. Risks of second primary malignancy in patients with cutaneous and ocular melanomas in Denmark, 1943-1989
33. Second primary cancers in patients with cutaneous malignant melanoma: A population-based study in Sweden
34. Incidence of invasive cancers following cutaneous malignant melanoma
35. Second primary cancers (SPC) in patients (PTS) with cutaneous malignant melanoma
36. Association between malignant melanoma and other primary malignancies (OPM)
37. ink4 mutations
38. The risk of subsequent primary cancer of the pancreas in patients with cutaneous malignant melanoma
39. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
40. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast Group Project P-1 Study
41. Preventing early steps leading to melanoma: Famesyl transferase inhibitors. Advances in melanoma management: Theory and practice in the 21st century